

9. Biegstraaten M, Arngrimsson R, Barbey F, et al. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the european fabry working group consensus document. Orphanet J Rare Dis. 2015 Mar 27; 10: 36 - 46.

Policy/UM Medical Management System Update History		
#	Date	Change Description
1.3	Effective Date: 10/06/2022	Annual review – no changes to the criteria at this time
1.0	Effective Date: 10/07/2021	Annual review of policy. No changes were made to the criteria
1.0	Effective Date: 10/08/2020	New policy created for this disease state and class of drugs. The Enzyme Replacement Therapy policy will be retired
1.0	Effective Date: □ □ □	0HGLFD0SROLFHVWDEOLVHG□

* The prescribing information for a drug is subject to change. To ensure you are reading the most current information it is advised that you reference the most updated prescribing information by visiting the drug or manufacturer website or <http://dailymed.nlm.nih.gov/dailymed/index.cfm>.